Jason A. Leverone, who serves as the Chief Financial Officer for OnKure Therapeutics, Inc. (NASDAQ:OKUR), executed a transaction involving the sale of 303 shares of the company's Class A Common Stock on June 22, 2026. The total value of this transaction was recorded at $1,332.
The shares were divested at prices fluctuating between $4.27 and $4.54 per share, resulting in a weighted average sale price of $4.3963. This specific sale was processed as an automatic transaction designed to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs). These units are governed under OnKure Therapeutics' 2023 RSU Equity Incentive Plan.
Following the completion of this transaction, Mr. Leverone's direct holdings in OnKure Therapeutics stand at 18,802 shares. These holdings encompass a mix of securities, including restricted stock units which represent a contingent right to receive one share of Class A Common Stock upon vesting. Additionally, his portfolio includes 3,105 shares acquired through the company's 2024 Employee Stock Purchase Plan on May 20, 2026.
Market data indicates that OnKure shares were trading at $4.34 at the time of reporting. Over the past year, the stock has delivered a 70% return. Data from InvestingPro highlights a significant price uptick over the last six months, with the stock climbing 52% during that period.
In broader corporate news, OnKure Therapeutics Inc. announced a private placement agreement that raised approximately $150 million in gross proceeds. This financing round was led by Access Biotechnology and included participation from notable investors such as BVF Partners LP and RA Capital Management. The capital raised will support OnKure's strategic shift to prioritize its next-generation PI3Kα pan-mutant programs. These programs specifically target breast cancer and vascular malformations using the OKI-345 and OKI-355 candidates.
Following this strategic pivot, Leerink Partners adjusted its price target for OnKure from $29 to $11, while maintaining an Outperform rating. This adjustment coincides with OnKure's move away from its previous lead asset, OKI-219, to focus on a broader PI3Kα pan-mutant approach. Leerink's rationale suggests this shift opens a larger addressable market. Conversely, Oppenheimer reiterated its Outperform rating for OnKure, maintaining a $30 price target in light of the company's pipeline changes. These analyst actions highlight OnKure's focus on expanding its therapeutic reach and addressing a wider patient population.
Market data for OnKure (OKUR) shows a closing price of $4.34, reflecting a change of +$0.140 or +3.33%. After-hours trading data indicates a price of $4.340 with no change. The stock's performance over various timeframes includes a 1-day change, 1-week change, 1-month change, 6-month change of 52%, 1-year change of 70%, and 5-year data. The chart data spans from 13:30 to 19:30, with price points including 3.84, 4.2, and 4.4.